“Latest Stem Cells News”

Vet-Stem Inc. announced that over 8000 animals have now been treated with Vet-Stem cell therapy.

Vet-Stem began providing stem cells to veterinarians in 2004 and has now provided stem cells for the treatment of over 8,000 animals. Vet-Stem was the first company to introduce rapid turnaround stem cell services in the US.

After providing stem cells for thousands of horses, Vet-Stem pioneered stem cell therapy in dogs and cats and is now the world leader in Regenerative Veterinary Medicine. The rapid adoption of stem cell therapy by equine veterinarians and horse owners provided a springboard for use in small animal veterinary medicine.

Greater than 75% of horses treated with Vet-Stem cell therapy for tendon and ligament injuries are able to return to their previous level of performance. Dog owners report that greater than 80% of dogs treated with Vet-Stem cell therapy have an improved quality of life.

Incoming search terms:

Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori’s APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function

Cytori Therapeutics announced today the publication of previously reported six-month outcomes from APOLLO, the Company’s European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction (heart attack or AMI), as Research Correspondence in the Journal of the American College of Cardiology. The APOLLO trial was a 14-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA) evaluating autologous ADRCs extracted with the Company’s proprietary Celution® System for the treatment of patients suffering from acute myocardial infarction.

In the APOLLO trial all patients were treated with standard-of-care and subsequently underwent an abdominal liposuction. Each patient’s adipose tissue was processed by the Celution® System where ADRCs were extracted, washed and concentrated into a syringe of clinical grade cells. Within 36 hours of the myocardial infarction and no longer than 24 hours after undergoing percutaneous coronary intervention, patients received an injection of either 20 million ADRCs (n=10) or a placebo (n=4).

Incoming search terms:

South Korea’s government drug agency cleared the way Thursday for commercial sales of what it called the world’s first approved medicine using stem cells collected from other people.

Cartistem, developed by Seoul-based Medipost, will help regenerate knee cartilage using stem cells developed from newborns’ umbilical cord blood, the Korea Food and Drug Administration said.

“Cartistem is… the world’s first approved allogeneic (taken from different individuals of the same species) stem cell drug, that can offer new opportunity for treatment of patients with degenerative arthritis,” the administration said in a statement.

Medipost said 27 billion won ($23.8 million) from private investors and government funds had been invested to develop Cartistem since 2001. The drug can be injected into a patient’s knees via surgery.

Clinical trials have been under way in the United States since last year, the statement said.

Two of the world’s top 10 drugmakers are in talks to seek a worldwide licence to make the drug, a Medipost spokesman told AFP, adding that final trials involving a large number of people would likely begin in the US in 2015 (…)

Cartistem, developed by Seoul-based Medipost, will help regenerate knee cartilage using stem cells developed from newborns’ umbilical cord blood, the Korea Food and Drug Administration said.

“Cartistem is… the world’s first approved allogeneic (taken from different individuals of the same species) stem cell drug, that can offer new opportunity for treatment of patients with degenerative arthritis,” the administration said in a statement (…)

Incoming search terms:

Transplanting own stem cells into heart of severe angina patients lessens their pain and improves their ability to walk, a new study has revealed.

The largest national stem cell study for heart disease showed that transplant subjects also experienced fewer deaths than those who didn’t receive stem cells.

In the 12-month Phase II, double-blind trial, subjects’ own purified stem cells, called CD34+ cells, were injected into their hearts in an effort to spur the growth of small blood vessels that make up the microcirculation of the heart muscle (…)

He also said that this study provides the first evidence that a person’s own stem cells can be used as a treatment for their heart disease. However, he cautioned that the findings of the 25-site trial with 167 subjects, require verification in a larger, Phase III study.

The stem cell transplant is the first therapy to produce an improvement in severe angina subjects’ ability to walk on a treadmill. Twelve months after the procedure, the transplant subjects were able to double their improvement on a treadmill compared to the placebo group (…)

from http://timesofindia.indiatimes.com/life/health-fitness/health/Your-own-stem-cells-can-help-treat-heart-disease/articleshow/5242519.cms

Incoming search terms:

Health Counselor Board, Javier Alvarez Guisasola, launched on Wednesday a clinical trial coordinated by Professor Margarita Calonge, IOBA’s on cell therapy applied to treat corneal blindness.
This study was coordinated by the IOBA and IBGM to demonstrate the long-term effectiveness of the epithelial stem cell transplantation of the cornea, previously cultivated to restore corneal blindness. Stem cells come from a healthy eye of the patient or family support.

Incoming search terms:

About five years ago, Professor Janet Sawicki at the Lankenau Institute in Pennsylvania read an article about nanoparticles developed by MIT’s Daniel Anderson and Robert Langer for gene therapy, the insertion of genes into living cells for the treatment of disease. Sawicki was working on treating ovarian cancer by delivering — through viruses — the gene for the diphtheria toxin, which kills tumor cells (…)

Incoming search terms: